Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab.

IF 4.8 2区医学 Q1 CLINICAL NEUROLOGY

Journal of Neurology Pub Date : 2025-04-04 DOI:10.1007/s00415-025-13027-x

Lucia Moiola, Alessandra Mandelli, Maciej Tarkowski, Annamaria Finardi, Arianna Gabrieli, Chiara Zanetta, Vittorio Viti, Irene Gattuso, Federica Esposito, Rosetta Pedotti, Erwan Muros-Le Rouzic, Catarina Raposo, Maria A Rocca, Massimo Locatelli, Chiara Bonini, Roberto Furlan, Agostino Riva, Massimo Filippi

{"title":"Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab.","authors":"Lucia Moiola, Alessandra Mandelli, Maciej Tarkowski, Annamaria Finardi, Arianna Gabrieli, Chiara Zanetta, Vittorio Viti, Irene Gattuso, Federica Esposito, Rosetta Pedotti, Erwan Muros-Le Rouzic, Catarina Raposo, Maria A Rocca, Massimo Locatelli, Chiara Bonini, Roberto Furlan, Agostino Riva, Massimo Filippi","doi":"10.1007/s00415-025-13027-x","DOIUrl":null,"url":null,"abstract":"Background: Utility of repeated boosts of anti-SARS-CoV-2 vaccination in persons with MS (pwMS) treated with ocrelizumab is questioned.Objective: Investigate antiviral antibody and T-cell responses after mRNA vaccination for SARS-CoV-2 in ocrelizumab-treated pwMS.Methods: Peripheral blood mononuclear cells were stimulated with SARS-CoV-2 peptide pools and T-cell reactivity was assessed by ELISPOT for IFN-γ detection, and by multiparametric flow cytometry analyses for assessment and characterization of T-cell activation. Anti-SARS-CoV-2 spike and nucleocapsid antibodies were analyzed in plasma of pwMS using two commercial platforms.Results: ELISPOT assay against the spike protein of SARS-CoV-2 showed that COVID vaccination with mRNA results in the development of a robust specific T-cell reactivity that is sustained over repeated cycles of vaccination and tends to decline 2 years after last boost. Flow cytometry analysis following stimulation with SARS-CoV-2 peptide pools confirmed the presence of CD8+ T memory stem cells. CD8+ T memory stem cells, in particular, increased after repeated boosts of vaccination, as occurred for anti-SARS-CoV-2 antibodies.Conclusions: Repeated cycles of vaccination increase T and B-cell reactivity against SARS-CoV-2.","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":"272 4","pages":"314"},"PeriodicalIF":4.8000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00415-025-13027-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Utility of repeated boosts of anti-SARS-CoV-2 vaccination in persons with MS (pwMS) treated with ocrelizumab is questioned.

Objective: Investigate antiviral antibody and T-cell responses after mRNA vaccination for SARS-CoV-2 in ocrelizumab-treated pwMS.

Methods: Peripheral blood mononuclear cells were stimulated with SARS-CoV-2 peptide pools and T-cell reactivity was assessed by ELISPOT for IFN-γ detection, and by multiparametric flow cytometry analyses for assessment and characterization of T-cell activation. Anti-SARS-CoV-2 spike and nucleocapsid antibodies were analyzed in plasma of pwMS using two commercial platforms.

Results: ELISPOT assay against the spike protein of SARS-CoV-2 showed that COVID vaccination with mRNA results in the development of a robust specific T-cell reactivity that is sustained over repeated cycles of vaccination and tends to decline 2 years after last boost. Flow cytometry analysis following stimulation with SARS-CoV-2 peptide pools confirmed the presence of CD8⁺ T memory stem cells. CD8⁺ T memory stem cells, in particular, increased after repeated boosts of vaccination, as occurred for anti-SARS-CoV-2 antibodies.

Conclusions: Repeated cycles of vaccination increase T and B-cell reactivity against SARS-CoV-2.

查看原文本刊更多论文

在接受ocrelizumab治疗的多发性硬化症患者中，召回疫苗可增加可检测的b细胞反应性。

背景：在接受ocrelizumab治疗的多发性硬化症（pwMS）患者中反复加强抗sars - cov -2疫苗接种的效用受到质疑。目的：观察ocrelizumab治疗的pwMS接种SARS-CoV-2 mRNA后的抗病毒抗体和t细胞应答。方法：用SARS-CoV-2肽池刺激外周血单个核细胞，用ELISPOT检测IFN-γ检测t细胞的反应性，用多参数流式细胞术分析t细胞活化的评估和表征。采用两种商业平台分析pwMS血浆中抗sars - cov -2刺突抗体和核衣壳抗体。结果：针对SARS-CoV-2刺突蛋白的ELISPOT检测显示，用mRNA接种COVID疫苗可产生强大的特异性t细胞反应性，这种反应性在重复接种周期中持续存在，并在最后一次增强后2年呈下降趋势。用SARS-CoV-2肽池刺激后的流式细胞术分析证实了CD8+ T记忆干细胞的存在。特别是CD8+ T记忆干细胞在反复接种疫苗后增加，就像抗sars - cov -2抗体一样。结论：重复接种周期可增加T细胞和b细胞对SARS-CoV-2的反应性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Neurology 医学-临床神经学

CiteScore

10.00

自引率

5.00%

发文量

558

审稿时长

1 months

期刊介绍： The Journal of Neurology is an international peer-reviewed journal which provides a source for publishing original communications and reviews on clinical neurology covering the whole field. In addition, Letters to the Editors serve as a forum for clinical cases and the exchange of ideas which highlight important new findings. A section on Neurological progress serves to summarise the major findings in certain fields of neurology. Commentaries on new developments in clinical neuroscience, which may be commissioned or submitted, are published as editorials. Every neurologist interested in the current diagnosis and treatment of neurological disorders needs access to the information contained in this valuable journal.